Literature DB >> 23562852

Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.

Russell E Poland1, Ira M Lesser, Yu-Jui Yvonne Wan, Lev Gertsik, Jie Yao, Leslie J Raffel, Keh-Ming Lin, Hector F Myers.   

Abstract

AIMS: Ethnic differences in genotype frequency provide a natural condition for assessing the contribution of gene variations to the causes and treatments of disease. Accordingly, the purpose of this study was to determine whether ethnic variations in allele frequencies of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) of the SLC6A4 gene were related to the response to the treatment of depression. MAIN
METHODS: African-Americans (n=101) and Caucasians (n=100) with major depressive disorder were treated with the antidepressant citalopram (20-60mg/day) for 8weeks. Genotyping for the long (L) and short (s) alleles (LL, Ls, and ss) of the SLC6A4 gene was performed and the association between genotype and treatment response was assessed. KEY
FINDINGS: Subjects in both ethnic groups showed a significant reduction in depression scores over time (p<.0001). However, in spite of a significantly greater frequency of the L allele in African-Americans as compared to Caucasians, a comparable clinical response between the two groups was found with 5-HTTLPR polymorphism not significantly associated with clinical response in either ethnic group. SIGNIFICANCE: The results are consistent with a previous finding and in accord with most of the results obtained in Caucasian subjects that SLC6A4 genotype is not related, at least by itself, to a response to treatment in either ethnic group to any clinically significant degree.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562852      PMCID: PMC3786570          DOI: 10.1016/j.lfs.2013.03.009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  20 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.

Authors:  K P Lesch; D Bengel; A Heils; S Z Sabol; B D Greenberg; S Petri; J Benjamin; C R Müller; D H Hamer; D L Murphy
Journal:  Science       Date:  1996-11-29       Impact factor: 47.728

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Social support and undermining in close relationships: their independent effects on the mental health of unemployed persons.

Authors:  A D Vinokur; M van Ryn
Journal:  J Pers Soc Psychol       Date:  1993-08

5.  Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.

Authors:  M A Anderson; J F Gusella
Journal:  In Vitro       Date:  1984-11

6.  Circadian patterns of rat anterior pituitary and target gland hormones in serum: determination of the appropriate sample size by statistical power analysis.

Authors:  R E Poland; R T Rubin; M E Weichsel
Journal:  Psychoneuroendocrinology       Date:  1980       Impact factor: 4.905

7.  Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects.

Authors:  J Gelernter; H Kranzler; J F Cubells
Journal:  Hum Genet       Date:  1997-12       Impact factor: 4.132

8.  Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

Authors:  Jeffrey B Kraft; Eric J Peters; Susan L Slager; Greg D Jenkins; Megan S Reinalda; Patrick J McGrath; Steven P Hamilton
Journal:  Biol Psychiatry       Date:  2006-11-21       Impact factor: 13.382

9.  Serotonin transporter promoter polymorphism in African Americans : allele frequencies and implications for treatment.

Authors:  Francis E Lotrich; Bruce G Pollock; Robert E Ferrell
Journal:  Am J Pharmacogenomics       Date:  2003

10.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.

Authors:  E Smeraldi; R Zanardi; F Benedetti; D Di Bella; J Perez; M Catalano
Journal:  Mol Psychiatry       Date:  1998-11       Impact factor: 15.992

View more
  5 in total

Review 1.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 3.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

4.  Genetic Moderators of the Impact of Physical Activity on Depressive Symptoms.

Authors:  V M Dotson; F C Hsu; T Y Langaee; C W McDonough; A C King; R A Cohen; A B Newman; S B Kritchevsky; V Myers; T M Manini; M Pahor
Journal:  J Frailty Aging       Date:  2016

5.  Pharmacodynamic Gene Testing in Prader-Willi Syndrome.

Authors:  Janice Forster; Jessica Duis; Merlin G Butler
Journal:  Front Genet       Date:  2020-11-20       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.